Finance

Results: 697-708 of 41389

Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture

PR Newswire associated0

ASSAÍ ENDS FIRST QUARTER WITH CONSISTENT CASH GENERATION, LEVERAGE REDUCTION, AND MARKET SHARE GAINS

BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs

PR Newswire associated0

NYSE Content Update: Joby Aviation Rings Opening Bell Following NYC Test Flight

Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right)

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder

World's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceutical

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care

Thomas Coesfeld and Bob Valentine, Courtesy of BMG and Concord

BMG and Concord Combine to Create World’s Leading Independent Music Company

New shares of Bioretec Ltd registered with the trade register

Masimo RD SET® Neo Pulse Oximetry Sensor

Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study

PR Newswire associated0

Benvenuti! Alaska Airlines launches historic first nonstop flight between Seattle and Rome

PR Newswire associated0

Echosens Appoints Romain Baujard as Group Chief Executive Officer